Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01632-x
Abstract: Galcanezumab, a humanized monoclonal antibody that binds to calcitonin gene-related peptide, is approved for the preventive treatment of migraine in adults. It is self-administered once monthly as a subcutaneous injection. This paper describes the time… read more here.
Keywords: migraine; galcanezumab; maintenance; treatment ... See more keywords
Galcanezumab: First Global Approval
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-1002-7
Abstract: Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018,… read more here.
Keywords: migraine; galcanezumab; galcanezumab first; migraine adults ... See more keywords
Galcanezumab for the prevention of cluster headache
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1800635
Abstract: ABSTRACT Introduction Cluster headache (CH) is among the worst painful conditions. The available therapies are scarce and not specific, leaving many patients unsatisfied because of poor efficacy and/or tolerability. Patients not responding to common treatments… read more here.
Keywords: galcanezumab prevention; prevention cluster; cluster headache; galcanezumab ... See more keywords
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
Sign Up to like & getrecommendations! Published in 2018 at "Headache"
DOI: 10.1111/head.13427
Abstract: To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. read more here.
Keywords: episodic migraine; galcanezumab; 100 response; response rate ... See more keywords
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Sign Up to like & getrecommendations! Published in 2018 at "Cephalalgia"
DOI: 10.1177/0333102417747230
Abstract: Background Safety findings from a Phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (NCT02163993) are reported here. Methods Patients aged 18–65 years with episodic migraine were… read more here.
Keywords: phase; galcanezumab; treatment; study ... See more keywords
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
Sign Up to like & getrecommendations! Published in 2020 at "Cephalalgia"
DOI: 10.1177/0333102420905321
Abstract: Objective To report efficacy and safety of galcanezumab in adults with chronic cluster headache. Background Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its biological activity. Methods This study… read more here.
Keywords: galcanezumab; treatment; period; placebo ... See more keywords
Galcanezumab modulates Capsaicin-induced C-fiber reactivity
Sign Up to like & getrecommendations! Published in 2022 at "Cephalalgia"
DOI: 10.1177/03331024221112906
Abstract: Background The vasodilatory calcitonin-gene related peptide (CGRP) is understood as pivotal mediator in migraine pathophysiology. Blocking CGRP with small molecules or monoclonal antibodies (CGRP-mAb) reduces migraine frequency. However, prescription of CGRP-mAbs is still regulated and… read more here.
Keywords: capsaicin induced; blood flow; dermal blood; galcanezumab ... See more keywords
Photophobia and migraine outcome during treatment with galcanezumab
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2022.1088036
Abstract: Background Calcitonin gene-related peptide (CGRP) plays a pivotal role in migraine physiology, not only regarding migraine pain but also associated symptoms such as photophobia. The aim of the present study was to assess monoclonal antibodies… read more here.
Keywords: improvement; migraine; photophobia migraine; galcanezumab ... See more keywords